tbuckley/cabot-search huggingface dataset:
BEAM as a Frontline High Dose Chemotherapy Supported by Autologous PBSCT in Elderly Patients (≥60 Years) with Diffuse Large B-Cell Lymphoma (DLBCL): Comparison with Younger Cohort of Patients.
Authors: V. Ivanov, D. Coso, J. Rey, T. Aurran, A.-M. Stoppa, J.-M. Schiano de Collela, J.-A. Gastaut, Didier Blaise, R. Bouabdallah
Journal: Blood (2007)
Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent
Authors: Paulina Pechanska, Joachim Kunz, Tobias Rausch, Obul Reddy Bandapalli, Elena Orlova, Judit Sagi, Martin Stanulla, Martin Schrappe, Renate Kirschner-Schwabe, Jana Hof, Cornelia Eckert, Rolf Köhler, Martina U. Muckenthaler, Jan o. Korbel, Andreas E Kulozik
Journal: Blood (2015)
Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile
Authors: Michael D. Amatangelo, Paola Neri, Maria Ortiz, Chad C. Bjorklund, Anita K. Gandhi, Anke Klippel, Nizar J Bahlis, Tom Daniel, Rajesh Chopra, Matthew Trotter, Anjan Thakurta
Journal: Blood (2015)
SAT0365 Risk Factors for Visual Loss in Giant Cell Arteritis (GCA)
Authors: R. Solans-Laqué, G. Fraile, B. Escalante, E. Fonseca, A. Martinez-Zapico, M. Perez-Conesa, M. Abdilla, M. Montegaudo, L. Caminal, B. Gracia, M.J. Del Castillo, P. Fanlo, M. Ramentol
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> visual loss is the most frequent ischemic complication and the main cause of permanent disability among patients with GCA. To identify factors related to this complication may help physicians to start an early treatment and assay new therapies <h3>Objectives</h3> To analyse clinical and histological findings related to visual loss in patients with GCA <h3>Methods</h3> demographic, clinical and histological features of patients with biopsy-proven GCA recruited at 10 Hospitals from Spain (REVAS Study) were analysed. Statistical analysis was performed using SPSS vs. 20 <h3>Results</h3> 418 patients were included: 290 (69.4%) females (ratio F/M: 2.3/1). The mean age at diagnosis was 75.5 ± 7 (53–92), 55% patients being older than 75y. The median diagnosis delay was 7 weeks (IQR 4–12). Cardiovascular risk factors were present in 45% of patients (hypertension in 48.8%, hypercholesterolemia in 26.6%, diabetes mellitus in 19.4%). The most frequent symptoms at CGA diagnosis were recent onset headache (81%), constitutional symptoms (47%) and polymyalgia rheumatic (44.5%). Jaw claudication, cranial hyperesthesia and amaurosis fugax were reported by 44.5%, 31.8% and 16.5%2 of patients, respectively. A total of 84 patients suffered vision loss (in 4 cases involving both eyes), due to anterior optic ischemic neuropathy (AION) in 78 (92.8%), and to central retinal artery occlusion in 6 (7.1%). CVA was recorded in 6.5% of cases. Anemia was present in 76.3% of patients. Mean ESR was 98±23.4. Patients with visual loss presented more frequently jaw claudication (71.6% vs 39.2%), cranial hyperesthesia (52.6% vs 28.7%) and amaurosis fugax (52.6% vs 8.6%), and less frequently low-grade fever (16.7% vs 43.1%) and toxic syndrome (37.2% vs 53.4%). Regarding to histological findings: patients with visual loss presented on TAB more intimal hyperplasia (70.5% vs 57.7%) and lumen occlusion &gt;50% (53.8 vs 19.4%). No other differences were found. Univariated analysis showed than AION was significantly related to the presence of amaurosis fugax (OR 12.8, 95% CI 7.0–23.3, p&lt;0.001), jaw claudication (OR 4, 95%CI 2.3–7.1, p&lt;0.001), cranial hyperesthesia (OR 2.4, 95%CI 1.5–4), and age at diagnosis ≥75 years old (OR 2.7, 95% CI 1.5–4.6, p&lt;0.001). An inverse relationship between AION and the presence of low-grade fever and toxic syndrome was found. No significant relationship was found between visual loss development and cardiovascular risk factors or CVA <h3>Conclusions</h3> AION is the most frequent cause of vision loss in GCA. Jaw claudication, cranial hyperesthesia, amaurosis fugax, and age &gt;75 older at diagnosis are significantly related to AION. A wider recognition of the disease would potentially reduce the prevalence of irreversible visual loss among GCA patients. <h3>Disclosure of Interest</h3> None declared
THU0510 A Longitudinal Dual Energy Computed Tomography Study on The Effect of Urate Lowering Therapies on The Reduction of Tophus Burden in Patients with Chronic Gout
Authors: H. Ellmann, S. Bayat, I. d'Òliveira, M. Englbrecht, E. Araujo, S. Mendonca, A. Cavallaro, M. Lell, B. Manger, G. Schett, J. Rech
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Dual energy computed tomography (DECT) allows reliably detecting and quantifying tophus burden in patients with chronic gout. Longitudinal studies on the effect of uric acid lowering drug therapy on tophus burden assessed by DECT are currently lacking with the exception of a small study performed in patients treated with pegloticase (1) <h3>Objectives</h3> To assess the effects of uric acid lowering drug therapy to reduce tophus volume in patients with chronic gout <h3>Methods</h3> Follow-up DECT scans were performed in 94 patients with DECT+ chronic gout receiving stable treatment with either allopurinol, febuxostat, benzbromaron or pegloticase, or had life-style intervention only with no concomitant uric acid lowering drug therapy. Baseline and follow-up scans of both feet captured tophus volume by <i>Syngo DE Gout</i> software (Siemens). Artefacts were manually excluded. Changes in tophus volume were calculated in a descriptive (tophus volume at baseline minus tophus volume at follow-up) and inferential way (Wilcoxon signed-rank test). Demographic data, medication and blood values (CRP, creatinine, serum urate) were recorded at the time of DECT scan. <h3>Results</h3> 94 patients (75 men and 19 women) were analyzed. Mean disease duration until the first DECT examination was 3.3 years and mean interval between both DECT examinations was 1.5 years. The overall baseline serum uric acid level decreased from 7.3 ± 2.5 mg/dl to 5.9 ± 2.8 mg/dl at follow up. Baseline tophus volume decreased by 77% with allopurinol (p&lt;0.001, r=-0.50), 35% with febuxostat (p=0.001, r=-0.51) and 90% with pegloticase (p=0.005, r=-0.58). Only 2 patients were treated with benzbromaron showing numerical decrease of tophus volume at a similar range as seen with allopurinol (-75%). Life-style intervention also led to a moderate (-31%), though significant (p=0.007, r=-0.40), decrease in tophus burden. <h3>Conclusions</h3> Sustained uric acid lowering drug therapy leads to significant reduction of DECT tophus burden in chronic gout patients. Tophus reduction depends on initial tophus volume. <h3>References</h3> ) Tophus resolution with pegloticase: a prospective dual-energy CT study. Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A, Hueber AJ, Cavallaro A, Lell M, Dalbeth N, Manger B, Schett G, Rech J. RMD Open. 2015 Jun 17;1(1):e000075. doi: 10.1136/rmdopen-2015-000075. eCollection 2015. <h3>Disclosure of Interest</h3> None declared
Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421
Authors: Norman J. Lacayo, Aileen Cohen, Matt Westfall, Alan Lackey, Xiaohua (Robert) Xin, Urte Gayko, Santosh Putta, Soheil Meshinchi, Susana C. Raimondi, Todd A. Alonzo, Robert J. Arceci, Yaddanapudi Ravindranath, Gary Van Houten Dahl, Alessandra Cesano
Journal: Blood (2010)
Th17-Derived Memory Cells Are Long-Lived and Retain a Stem-Like Molecular Signature
Authors: Pawel Muranski, Zachary Borman, Sid Kerkar, Yun Ji, Luca Gattinoni, Reger N Robert, Luis Sanchez-Perez, Klebanoff A Christopher, Zhiya Yu, Kern J Steven, Gabriela Ferreyra, Robert L Danner, Nicholas P Restifo
Journal: Blood (2010)
P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline?
Authors: C. Hoener Zu Siederdissen, F. Rinker, C. Falk, N. Filmann, B. Maasoumy, K. Deterding, K. Port, C. Mix, E. Herrmann, H. Wedemeyer, M.P. Manns, A. Kraft, M. Cornberg
Journal: Journal of Hepatology (2015)
Pharmacokinetics (PK) of Mycophenolate Mofetil (MMF) in Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Are Associated with Significantly Higher Clearance.
Authors: Olga Militano, Kate Roache, Leslie M. Shaw, Michael Figurski, Prakash Satwani, Janet Ayello, Karen Wolownik, Sandra Foley, Ria Hawkes, Gustavo Del Toro, M. Brigid Bradley, Diane George, James Garvin, Monica Bhatia, Liz Roman, Mitchell S. Cairo
Journal: Blood (2005)
Myeloablative Conditioning of Patients with Myelofibrosis with Myeloid Metaplasia Using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT) with High Doses of CD34+ Cells Results in Hematologic Responses - 32 Months Follow-Up of Three Patients and Short-Term Results of a New Study.
Authors: Stefan Fruehauf, Eike C. Buss, Julian Toplay, Hans H. Kreipe, Anthony D. Ho
Journal: Blood (2005)
P09.08 Clinical validation of integrated diagnosis in low-grade glioma (LGG)
Authors: M. Rossi, M. Conti Nibali, M. Riva, B. Fernandes, F. Pessina, R. Soffietti, P. Navarria, A. Bikfalvi, L. Bello
Journal: Neuro-Oncology (2016)

AbstractThe importance of adding molecular data to histology for better stratifying tumor patients has been recently proposed by WHO; an integrated diagnosis has been recommended for routine pathological practice, in which molecular data obtained from the most representative area of the tumor are associated to histological appearance. We have evaluated the impact of the integrated diagnosis classification on LGGs progression in a series of tumors operated in our center. Inclusion criteria were a) histological diagnosis of grade II diffuse gliomas; b) full radiological, surgical and clinical data on admission and at follow up (mean 6.3 years (5–9 years), to evaluate extent of resection (EOR), seizure control, eventual treatment and PFS; c) presence of IDH1 mutation. 242 patients fulfilled the criteria and were reevaluated according to integrated diagnosis. Tumors initially classified as 101 oligodendrogliomas, 76 astrocytomas, and 65 oligoastrocytomas, were reclassified accordingly as 167 grade II oligodendrogliomas and 75 astrocytomas. Tumors were then further stratified according to EOR and seizure control in low (79,3%) and high (20,7%) risk. The impact of tumor reclassification was evaluated in term of PFS, looking at the rate of recurrence, divided as early (within 3 years from surgery) and late (after 5 years), and rate of malignant transformation. When tumors were classified according to traditional histological subgroups (oligodendrogliomas, astrocytomas, mixed gliomas) PFS of oligodedrogliomas was better than that of astrocytomas (5.3 vs 4.2 yrs) but without reaching statistical difference. When classified according to integrated diagnosis, some flaws appeared as showed by the occurrence of early recurrence (5,9%) and malignant transformation (5,1%) even in tumors with the best clinical (GTR) and molecular prognostic factors (IDH1 mut, codelation). True astrocytoma (IDH1 mut, ATRX loss, no codel) did worst then true oligodendroglioma (26,8% early recurrence and 10,7% malignant transformation, in low risk).These data indicate that integrated diagnosis a) better stratified patients than traditional histology, b) still does not fully describe the biological behavior of the tumor. Additional biological markers may be also important for additionally stratify LGGs.
Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia
Authors: Ronan T. Swords, Tino Schenk, Sven Stengel, Veronica Sylvina Gil, Kevin R. Petrie, Aymee Perez, Rodriguez Ana, Justin M. Watts, Fernando Vargas, Roy Elias, Arthur Zelent
Journal: Blood (2015)
Dizziness and Vertigo during MRI
Authors: Bryan Ward, David Zee
Journal: New England Journal of Medicine (2016)

A 33-year-old man participating in a research study underwent MRI in a 7-tesla MRI scanner. On entering the scanner, he had a spinning sensation for 2 minutes. Nystagmus, recorded with infrared goggles and shown in a video, continued for the entire 90-minute scanning period.
PTU-131 Intermediate Faecal Calprotectin: A Positive Ornegative Result? Observations of A Retrospective Study
Authors: K Wright, J Kennedy, L Materacki, S Waterman, R Makins, A Di Mambro
Journal: Gut (2016)

<h3>Introduction</h3> Faecal Calprotectin (FC) can be used to distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). NICE guidelines advise a cut-off of 50 micrograms/g when differentiating between the two; however, an area of diagnostic uncertainty exists with levels between 50 mcg/g and 150 mcg/g. We reviewed our practice with this group assessing underlying pathology, identifying confounding factors and suggesting a streamlined assessment pathway to reduce unnecessary investigations <h3>Methods</h3> Retrospective, observational study of all Intermediate FC results from September 2014–15. Data collated from biochemical requests, known IBD patients excluded. Clinical letters, pathology results and endoscopy reports interrogated to build a detailed data set <h3>Results</h3> 82 patients had a FC between 51–150 mcg/g, 56 females, mean age of 42.4 years. Diarrhoea was predominant in 67, constipation: 9, variable bowel habit: 7 with 41 reporting pain. Red flag symptoms were identified in 17 patients. NICE and BSG guidelines recommend testing FBC, CRP, ESR/PV and tTG when assessing for IBS and IBD. Only 19% of our patients had the full complement of tests. PV was least frequently tested, seen in only 31% of patients. TTG was checked in 83%, CRP in 69% and FBC in 81%. 46 patients had endoscopic investigations. Of those, 25 had no red flag symptoms or abnormalities identified on bloods. 17 of these scopes were reported as normal. 2 found evidence of ulceration within the bowel; however, histology excluded IBD and both patients were treated as IBS. Factors contributing elevated FC include non-steroidal inflammatory drugs (NSAIDS), proton pump inhibitors (PPIs), polyps and gastrointestinal (GI) infections. Of our patients; 27 were using PPIs, 7 NSAIDS, 8 had polyps and 5 had recent or ongoing GI infections. None of the patients were found to have IBD at the time of FC requesting or to date. 50 patients were given a confirmed diagnosis of IBS <h3>Conclusion</h3> FC can be elevated for a variety of reasons. A cut off of 150 mcg/g appears reliable for excluding IBD. Red flag symptoms and organic disease should always be considered. NICE and BSG guidelines recommend checking FBC, CRP, PV and tTG. As demonstrated here, this can be overlooked, delaying diagnosis. Confounding factors should be considered and eliminated where possible. In the absence of organic disease, with symptoms fitting criteria for IBS as defined by ROME III, invasive imaging has not been shown to aid or alter the clinical diagnosis. Patients can be referred to primary care and managed as per local guidelines. FC may be retested at 3 months. If it remains elevated, luminal investigations could then be initiated. A prospective audit is being carried out to validate this pathway <h3>Disclosure of Interest</h3> None Declared
Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group
Authors: Remy Gressin, Mary Callanan, Nicolas Daguindau, Adrian Tempescul, Sylvain Carras, Marie Pierre Moles, Guillaume Cartron, Roch Houot, Caroline Dartigeas, Jean Michel Pignon, Selim Corm, Anne Banos, Christiane Mounier, Jehan Dupuis, Margareth Macro, Joel Fleury, Fabrice Jardin, Lionel Karlin, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorvaux, Krimo Bouabdallah, Sandy Amorin, Reda Garidi, Laurent Voillat, Bertrand Joly, Katell Le Dû, Nadine Morineau, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Steven Le Gouill, Ghandi Damaj
Journal: Blood (2014)
PTH-148 Comparing Dietitian-Led Group Clinics to Individual Appointments for Newly Diagnosed Patients with Coeliac Disease (CD)
Authors: N Trott, M Kurien, F Branchi, DS Sanders
Journal: Gut (2016)

<h3>Introduction</h3> Newly diagnosed CD patients should have a nutritional assessment and gluten-free diet (GFD) education by registered dietitians, in accordance with guidelines. Achieving these standards is problematic due to increased CD diagnosis and limited trained dietitians available to deliver these services. Locally, we have shown that patients often wait four to six weeks for a dietetic consultation following CD diagnosis, with patient feedback suggesting this is unacceptably long. This study aimed to address this concern by comparing whether dietetic consultations provided in group clinics was non-inferior to an individual appointment for newly diagnosed CD patients. <h3>Methods</h3> Between January 2015 and December 2015 newly diagnosed CD patients were seen either by a dietitian in a group clinic or in an individual appointment as part of a local service evaluation project. Group clinics were defined as having a minimum of 6 individuals, and covered the same topics as individual appointments (education on gluten-free diets, prescriptions, travelling and information on Coeliac UK). All patients had nutritional assessments at baseline and bloods performed in accordance with BSG guidelines. These were reassessed at 3 month follow-up appointments, alongside evaluation forms for clinics and assessment of GFD adherence using the Biagi score (A validated 5 point adherence score (0–4), with the highest score indicating strict GFD adherence). Comparisons between groups were made using a student t-test, with a p-value &lt;0.05 considered significant. <h3>Results</h3> 56 new CD patients were initially referred for a dietetic consultation. Eight patients (14%) did not attend first appointments and 8 failed to attend follow-up. Of the remaining 40 patients (25 F:15 M, mean age 48 years), 30 were seen in group clinics and 10 had individual appointments. There was no statistically significant difference in baseline BMI (p = 0.57), age (p = 0.10) or tissue transglutaminase antibody levels (p = 0.54) between group patients and individual clinic patients. At follow-up mean GFD adherence scores were similar in both groups (3.3 vs 3.1, p = 0.51), with paired t-tests showing significant reduction in both groups in serological markers and haematinics (p &lt; 0.001). Evaluation forms supported the merits of group clinics, with 97% (29/30) of patients stating that group clinics met expectations, enhanced understanding and that they would recommend to other patients. <h3>Conclusion</h3> This study demonstrates how group dietetic clinics for newly diagnosed patients may be a resource saving intervention, which derives no detriment to patient education and GFD adherence. Findings from this work provide proof of concept for undertaking a future randomised controlled trial in this area, including health economic analysis. <h3>Disclosure of Interest</h3> None Declared
Evaluation of Response to Anti-CD20 (Rituximab) Trial in Relapsed Follicular Lymphoma after Six Years in Follow-Up.
Authors: Araceli Rubio-Martinez, Luis Palomera, Valle Recasens, Maria J. Najera, Matilde Perella, Fernando Puente, Luis Perdiguer, Daniel Rubio-Felix, Pilar Mayayao, Pilar Giraldo
Journal: Blood (2005)
Association of Anesthesia and Surgery During Childhood With Long-term Academic Performance
Authors: Pia Glatz, Rolf H. Sandin, Nancy L. Pedersen, Anna-Karin Bonamy, Lars I. Eriksson, Fredrik Granath
Journal: JAMA Pediatrics (2016)

The results of preclinical studies suggest that anesthetic drugs administered to neonatal animals cause widespread neuronal apoptosis and later neurocognitive impairment. Adequately powered studies in the pediatric surgical population are scarce, and it is unclear whether such preclinical findings are relevant for the pediatric setting.To examine the association of anesthesia and surgery before age 4 years with long-term academic and cognitive performance indexed by school grades at age 16 years and IQ test scores at military conscription.This investigation was a cohort study among all children born in Sweden between January 1973 and December 1993. The dates of analysis were April 2013 to October 2015. Among all 2 174 073 Swedish children born between 1973 and 1993, we identified a primary study cohort of 33 514 children with 1 anesthesia and surgery exposure before age 4 years and no subsequent hospitalization and 159 619 matched unexposed control children. In addition, 3640 children with multiple surgical procedures before age 4 years were studied.Having at least 1 surgical procedure in the Swedish Patient Register before age 4 years.The mean school grades at age 16 years and IQ test scores at military conscription at age 18 years. The mean difference between the exposed cohort and unexposed cohort was estimated in a model that included sex, month of birth during the same year, gestational age at delivery, Apgar score at 5 minutes, maternal and paternal educational levels, annual taxable household income, cohabiting parents, and number of siblings.Among 33 514 exposed children (22 484 male and 11 030 female) and 159 619 unexposed children (105 812 male and 53 807 female) in the primary study cohort, 1 exposure before age 4 years was associated with a mean difference of 0.41% (95% CI, 0.12%-0.70%) lower school grades and 0.97% (95% CI, 0.15%-1.78%) lower IQ test scores. The magnitude of the difference was the same after multiple exposures. There was no difference in school grades with 1 exposure before ages 6 months, 7 to 12 months, 13 to 24 months, or 25 to 36 months. The overall difference was markedly less than the differences associated with sex, maternal educational level, or month of birth during the same year.Exposure to anesthesia and surgery before age 4 years has a small association with later academic performance or cognitive performance in adolescence on a population level. While more vulnerable subgroups of children may exist, the low overall difference in academic performance after childhood exposure to surgery is reassuring. These findings should be interpreted in light of potential adverse effects of postponing surgery.
SAT0500 A Comparative Analysis of Radiological Findings between Tuberculous and Brucellar Spondylodiscitis
Authors: S. Bouden, O. Saidane, I. Mahmoud, M. Sahli, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tuberculous and brucella spondylodiscitis are endemic in tunisia. Both present in various pathological patterns, but there are significant radiological differences that permit a presumptive aetiological diagnosis and orient the initial empirical treatment. <h3>Objectives</h3> The aim of this study was to compare radiological features between these two diseases. <h3>Methods</h3> A retrospective monocentric study was performed. Patients diagnosed with tuberculous spondylodiscitis (TSD) or brucellar spondylodiscitis (BSD) between 2008 and 2016 were included. Clinical status and radiological results were assessed. <h3>Results</h3> A total of 33 patients were enrolled in the study including 17 men and 16 women. The mean age was 59 years (29–96 years). Twenty four had TSD (72,8%) and 9 BSD (27,2%). CT scan was performed in 9 cases and magnetic resonance imaging (MRI) in 24 cases. For both TSD ans BSD the most common region affected wad lumbar spine (respectively 58% and 77%). Preverebral, paravertebral, epidural and psoas abscess formations were significantly more frequent in TSD compared with BSD [p=0,01]. When considering neurological complications such as epiduritis and cord compression, TSD was not significantly different from BSD [p=0,17]. <h3>Conclusions</h3> The results of this study show that TSD is a more suppurative disease with abscess formation. <h3>Disclosure of Interest</h3> None declared